Related Experiment Videos
Urinary prostaglandin E2 in the newborn and infant
Roberto Antonucci1, Laura Cuzzolin, Augusta Arceri
1Department of Pediatrics and Clinical Medicine-Section of Neonatal Intensive Care Unit, University of Cagliari, Cagliari, Italy.
Prostaglandins & Other Lipid Mediators
|July 24, 2007
Summary
Urinary Prostaglandin E(2) (PGE(2)) measurement offers a non-invasive way to assess kidney function in infants. This method helps investigate renal homeostasis in newborns facing health challenges or drug treatments.
Area of Science:
- Biochemistry
- Nephrology
- Pediatrics
Background:
- Prostaglandin E(2) (PGE(2)) is a lipid mediator crucial for kidney development and function.
- Renal PGE(2) regulates blood flow, filtration rate, and electrolyte balance, protecting the neonatal kidney.
- PGE(2) plays a role in neonatal renal stress and various kidney diseases.
Purpose of the Study:
- To review the use of urinary PGE(2) as a non-invasive marker.
- To assess renal homeostasis in newborns and infants.
- To examine its utility in physiological, pathological, and drug-treated conditions.
Main Methods:
- Literature review of studies measuring urinary PGE(2).
- Analysis of PGE(2) as an indicator of renal synthesis.
- Evaluation of its role in neonatal renal physiology and pathology.
Main Results:
- Urinary PGE(2) measurement is a sensitive index of renal synthesis.
- It reflects renal homeostatic function in early life.
- PGE(2) levels correlate with kidney status in various conditions.
Conclusions:
- Urinary PGE(2) is a valuable non-invasive marker for assessing neonatal kidney function.
- It aids in understanding renal homeostasis under diverse conditions.
- This marker can help monitor infants undergoing treatments with potentially nephrotoxic drugs.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...